Neuralstem, Inc. (CUR) Reaches $2.02 After 8.00% Down Move; Dermira (DERM)’s Sentiment Is 2.03

January 14, 2018 - By Darrin Black

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company has market cap of $1.14 billion. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It currently has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

The stock of Neuralstem, Inc. (NASDAQ:CUR) is a huge mover today! The stock decreased 2.88% or $0.06 during the last trading session, reaching $2.02. About 278,369 shares traded. Neuralstem, Inc. (NASDAQ:CUR) has risen 3.35% since January 14, 2017 and is uptrending. It has underperformed by 13.35% the S&P500.The move comes after 5 months negative chart setup for the $30.60M company. It was reported on Jan, 14 by Barchart.com. We have $1.86 PT which if reached, will make NASDAQ:CUR worth $2.45M less.




Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company has market cap of $30.60 million. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It currently has negative earnings. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome.

Since January 1, 0001, it had 0 insider purchases, and 12 sales for $1.50 million activity.

Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on February, 27. They expect $-1.31 EPS, down 523.81% or $1.10 from last year’s $-0.21 per share. After $-1.21 actual EPS reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts 8.26% negative EPS growth.

The stock increased 2.77% or $0.74 during the last trading session, reaching $27.44. About 1.06M shares traded or 99.85% up from the average. Dermira, Inc. (DERM) has declined 7.44% since January 14, 2017 and is downtrending. It has underperformed by 24.14% the S&P500.

Nea Management Company Llc holds 3.32% of its portfolio in Dermira, Inc. for 3.51 million shares. Venbio Select Advisor Llc owns 1.52 million shares or 3.18% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 1.88% invested in the company for 125,000 shares. The United Kingdom-based Abingworth Llp has invested 1.31% in the stock. Dafna Capital Management Llc, a California-based fund reported 75,500 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.